The Centers for Disease Control and Prevention, Chronic Viral Diseases Branch (CVDB), Division of Viral and Rickettsial Diseases (DVRD), National Center for Zoonotic Vector-borne and Enteric Diseases (NCZVED), Coordinating Center for Infectious Diseases (CCID), requires testing for 3q amplification using fluorescent in situ hybridization (FISH) assays on 100 exfoliated cervical samples from the EDRN cervical cancer biorepository. To the best of our knowledge only NeoDiagnostix of Rockville, MD has developed a clinical assay using Fluorescence In Situ Hybridization (FISH) to detect 3q26 copy number in cervical cells and under went a comprehensive validation of their assay. The Company's laboratory personnel are highly skilled in using diagnostic FISH assays to explore, detect, and diagnose genetic abnormalities in cancers, especially solid tumors. Their personnel have been trained at some of the world's most prestigious cancer research centers, including the National Cancer Institute and the Karolinksa. Their skills and experience are unique and well-suited to perform this work. The Company has also validated this diagnostic assay and offers its testing services through its CLIA-certified laboratory. Thus, we consider that NeoDiagnostix is the only company offering this service and award of a purchase order IAW/FAR Part 13 is contemplated to it. However, CDC will consider all responsible sources responding to the RFQ. All questions/concerns about the RFQ shall be submitted via e-mail ONLY to [email protected]. Vendor shall accomplish the testing within 7-10 days from receipt of order. The RFQ document will be available and posted at this site for downloading. No telephone requests of the solicitation will be accepted. No hard copy of the RFQ will be mailed. It is your responsibility to keep up with additional postings regarding the RFP on the FedbizOpps website

Bid Protests Not Available